Electrophysiologist-led Deep Sedation Protocols for Pulsed Field Ablation for Atrial Fibrillation… (NCT07149545) | Clinical Trial Compass
CompletedNot Applicable
Electrophysiologist-led Deep Sedation Protocols for Pulsed Field Ablation for Atrial Fibrillation Using a Bipolar Tip-Catheter: The DEEP-PFA Randomized Controlled Trial
China240 participantsStarted 2025-10-15
Plain-language summary
The DEEP-PFA trial is an investigator-initiated, prospective, single-center, three-arm (1: 1: 1), randomized controlled study comparing three anesthesia regimens-midazolam + fentanyl (DS1), flurbiprofen + midazolam + fentanyl (DS2), and dexmedetomidine + midazolam + fentanyl (DS3)-for non-airway-assisted pulsed-field ablation (PFA) in atrial fibrillation (AF). Patients scheduled for atrial fibrillation ablation at Beijing Anzhen Hospital will be screened for eligibility. Following signature of informed consent, patients who meets all inclusion criteria without any exclusion criteria, will be randomly assigned at a 1:1:1 ratio to one of three groups: (1) DS1: Traditional Midazolam Group (Midazolam + Fentanyl); (2) DS2: Enhanced Analgesia Group (Flurbiprofen + Midazolam + Fentanyl); or (3) DS3: Enhanced Sedation Group (Dexmedetomidine + Midazolam + Fentanyl). The primary endpoint of this study was the proportion of patients achieving a Ramsay sedation score of ≥3 at the start of ablation.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age 18-80 years
✓. Diagnosis of paroxysmal or persistent atrial fibrillation with clinical indication for catheter ablation
✓. Planned use of PFA as the ablation strategy
✓. Ability and willingness to provide written informed consent
Exclusion criteria
✕. Known hypersensitivity or allergy to study medications (fentanyl, midazolam, dexmedetomidine, flurbiprofen axetil)
✕. Heart failure NYHA class III-IV
✕. Severe obstructive sleep apnea syndrome
✕. Severe respiratory disease, significant hepatic or renal dysfunction, advanced malignancy, or comorbidities with expected survival \<1 year
✕. Pregnancy or breastfeeding
✕. Refusal to participate
What they're measuring
1
Proportion of patients with successful sedation at the start of ablation